- Home
- ONFO vs ALLR Comparison
ONFO vs ALLR Comparison
Compare ONFO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- ALLR
- Stock Information
- Founded
- ONFO 2018
- ALLR 2004
- Country
- ONFO United States
- ALLR United States
- Employees
- ONFO N/A
- ALLR N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- ALLR Health Care
- Exchange
- ONFO Nasdaq
- ALLR Nasdaq
- Market Cap
- ONFO 6.7M
- ALLR 6.0M
- IPO Year
- ONFO 2022
- ALLR N/A
- Fundamental
- Price
- ONFO $1.31
- ALLR $0.95
- Analyst Decision
- ONFO
- ALLR
- Analyst Count
- ONFO 0
- ALLR 0
- Target Price
- ONFO N/A
- ALLR N/A
- AVG Volume (30 Days)
- ONFO 18.5K
- ALLR 2.3M
- Earning Date
- ONFO 11-15-2024
- ALLR 03-07-2025
- Dividend Yield
- ONFO N/A
- ALLR N/A
- EPS Growth
- ONFO N/A
- ALLR N/A
- EPS
- ONFO N/A
- ALLR N/A
- Revenue
- ONFO $6,590,171.00
- ALLR N/A
- Revenue This Year
- ONFO $133.59
- ALLR N/A
- Revenue Next Year
- ONFO N/A
- ALLR N/A
- P/E Ratio
- ONFO N/A
- ALLR N/A
- Revenue Growth
- ONFO 29.25
- ALLR N/A
- 52 Week Low
- ONFO $0.39
- ALLR $0.90
- 52 Week High
- ONFO $1.88
- ALLR $264.00
- Technical
- Relative Strength Index (RSI)
- ONFO 48.15
- ALLR 40.42
- Support Level
- ONFO $1.35
- ALLR $0.91
- Resistance Level
- ONFO $1.48
- ALLR $1.03
- Average True Range (ATR)
- ONFO 0.11
- ALLR 0.09
- MACD
- ONFO 0.01
- ALLR -0.02
- Stochastic Oscillator
- ONFO 28.95
- ALLR 13.88
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.